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Purpose or Objective: The current standard of care for 
newly diagnosed papillary thyroid carcinoma invading the 
trachea is surgical resection followed by radioactive iodine 
therapy (RAI) and thyroid stimulating hormone suppression. 
However, the local recurrence rate is high. Several studies 
reported adjuvant external beam radiotherapy (EBRT) 
reduced the local recurrence. The benefit of adjuvant EBRT 
remains controversial. We evaluated the effect of adjuvant 
EBRT on local control in a single institution database. 
 
Material and Methods: Between May 2003 and October 2013, 
36 patients with locally advanced papillary thyroid carcinoma 
invading the trachea (pathologic stage T4) were treated with 
surgical resection. After surgery, 16 patients received 
adjuvant EBRT using intensity modulated radiation therapy 
followed by RAI, and 20 patients were treated with RAI 
alone. The age range was 36-87 years (median 64 years). 
EBRT doses ranged from 30-66 Gy (median 60 Gy). There was 
no statistically significant difference in terms of clinical 
characteristics between the EBRT and no EBRT groups. 
 
Results: Median follow up was 26.6 months (range, 16.5-40.1) 
in EBRT group, and 43.9 months (range, 13.9-117.6) in no 
EBRT group. There was no local or distant failure in EBRT 
group during the follow up. There were five local failures and 
one distant failure in no EBRT group. The two-year & five-
year local failure free survival rates were 95.0% and 49.8% in 
no EBRT group. There were acute grade 2 esophagitis (n=1) 
and grade 2 skin reaction (n=3). There were no grade 2 late 
complications in EBRT group. 
 
Conclusion: Adjuvant EBRT was found to be an effective 
treatment for local control in papillary thyroid carcinoma 
invading the trachea with tolerable complications, in a study 
at a single institution. Longer follow up will be required to 
demonstrate outcomes for tumor control and complications 
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Purpose or Objective: Locally advanced, high-risk cutaneous 
squamous cell carcinoma (CSCC) of the head and neck are 
typically aggressive and treated with combined modality 
therapy. These patients tend to be older, frail with multiple 
comorbidities which makes chemotherapy difficult to 
tolerate. Cetuximab is a monoclonal antibody against the 
EGFR receptor and has demonstrated activity in CSCC. We 
investigate the safety and efficacy of combined therapy in 
advanced, high risk CSCC with the addition of cetuximab. 
 
Material and Methods: Patients were identified with locally 
advanced CSCC with high risk or very high risk features who 
were treated with cetuximab and radiotherapy between 2006 
and 2013. A matched cohort over the same time period was 
identified who were treated with radiation. Propensity score 
analysis was performed with weighted factors including: 
Charlson Comorbidity Index score (age-adjusted), age. KPS, 
primary location, T and N stage, recurrent status, margin 
status, LVSI, PNI and grade. Overall survival, progression free 
survival and freedom from local or distant recurrence were 
evaluated with the Kaplan-Meier method for both the un-
adjusted and propensity score adjusted groups. Multivariate 
analysis was performed using cox proportional hazard models.  
Results: 29 patients were in the cetuximab and 39 in the 
control group. Median follow-up for alive patients was 30 
months. Patients in the cetuximab group were more likely to 
have advanced N stage, positive margins and recurrent 
disease. After propensity score matching the groups were 
well balanced. OS was not statistically significant between 
the two groups but depicted in Table 1 below there were 
approximately 20% more long term survivors in the cetuximab 
group after matching. Local control was 76% and 79% in the 
cetuximab and control groups, respectively. The rate of 
distant metastases was lower in the cetuximab group 6.8% 
versus 10%. The incidence of grade 2-3 toxicity was 41% in 
the cetuximab group. There was one grade 3 cetuximab 
acneiform rash, one grade 4 dysphagia and no grade 5 
toxicity.  
 
Table 1 Overall Survival Probabilities by year in both 




Conclusion: Although limited by small numbers, we found 
that there were more long-term survivors and less distant 
metastasis in the cetuximab group. This is the largest report 
of CSCC patients treated with cetuximab. In the absence of 
prospective data, we believe this data reveals that the 
addition of cetuximab is well tolerated and reveals signs of 
efficacy in this typically poor performing group of patients 
and should be pursued in clinical trials. 
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Purpose or Objective: Ki-67 index is used to assess cell 
proliferation during histopathological assessment of various 
tumours including high grade gliomas (HGG): Anaplastic 
astrocytoma, Anaplastic Oligodendroglioma and Glioblastoma 
Multiforme (GBM). We aimed to determine if there is a 
correlation between percentage staining of Ki-67 and overall 
survival in patients with HGG and determine a cut-point for 
percentage staining of Ki-67 that predicts for poorer survival. 
 
Material and Methods: Records of adult patients diagnosed 
with HGG on histopathological specimens examined at the 
Institute of Clinical Pathology and Medical Research at 
Westmead Hospital, NSW, between 1st of January 2002 and 
30th of July 2012 were identified. The specimens of these 
patients were examined for quantification of Ki-67 staining 
by two independent pathologists. Patient, disease, treatment 
and survival data were collected from hospital and cancer 
care service records. Descriptive statistical analyses were 
performed on the patient, disease and treatment data. 
Survival curves were constructed using Kaplan Meir methods. 
Using the minimum p value approach we obtained a cut-point 
for Ki-67 percentage staining that predicts for poorer 
survival. 
 
Results: Of the eligible 78 patients (median age = 57, range 
18 - 87) 46 (59 %) were males and 32 (41%) were females. 59 
(76%) patients were of ECOG performance status 0 -1. Seven 
patients had anaplastic astrocytoma or anaplastic 
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oligodendroglioma and the rest had GBM. There was a clear 
inverse correlation between Ki-67 percentage staining and 
overall survival. In patients with Ki-67 ≤ 30% (n=18), 5 year 
survival was approximately 50% compared to those with Ki-67 
>30% (n=60) with survival of 10% (logrank P-value 0.02, HR 
0.39, 95% CI 0.17 – 0.88). 
 
Conclusion: There appears to be a correlation between 
percentage staining of Ki-67 and overall survival in patients 
with HGG. Percentage staining of Ki-67 > 30% appears to 
predict for poorer survival in HGG. 
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Purpose or Objective:Background and purpose:In this 
retrospective evaluation, we correlated radiation dose 
parameters with occurrence of optical radiation-induced 
toxicities. 
 
Material and Methods: Patients and methods:213 
meningiomapatientsreceived radiation between 2000 and 
2013. Radiation dose and clinical datawere extracted from 
planning systems and patients’ files. The range of follow-up 
period was 2-159 months (median:75 months). 
 
Results: Results:Median age of patients was 60 years (range: 
23-86). There were163 female and 50 male patients. In 140 
cases, at least one of the neuro-optic structures (optic nerves 
and chiasm) was inside the irradiatedtarget volumes. We 
found 15 dry eye (7%) and 24 cataract (11.2%) cases. Median 
dose to affected lachrymal glands was 1.47Gy and median 
dose to affected lenses was1.05Gy. Age and blood cholesterol 
level in patients with cataract were significantly higher. 
Patients with dry eye were significantly older. Only 2 patients 
with visual problems attributable to radiation treatment 
(RION) were seen. They did not have any risk factors. 
Maximum and median delivered doses to neuro-optic 
structures were not higher than 57.30Gy and 54.60Gy 
respectively. 
 
Conclusion: Conclusion:Low percentages of cases with 
radiation induced high grade optic toxicities show that 
modern treatment techniques and doses are safe. In very few 
patients with optic side effects, doses to organs at risk were 
higher than the defined constraint doses. This observation 
leads to the problem of additional risk factors coming into 
play. The role of risk factors and safety of higher radiation 
doses in high grade meningiomas should be investigated in 
more comprehensive studies. 
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Purpose or Objective: Evaluating the radiation doses 
delivered to different parts of the visual pathway for better 
understanding of light vision in radiotherapy patients. 
 
Material and Methods: 20 patients with brain tumors and 
head and neck malignancies who received radiotherapy and 
experienced any kind of light or color vision during radiation 
treatment. All the components of visual pathway including 
lenses, eyeballs, retinas, optic nerves, chiasm, optic tracts, 
optic radiations and visual occipital cortexes were contoured. 
 
Results: 11 patients were male (55%) and 9 were female 
(45%). Age median was 56 years. The range of dose/fraction 
and total prescribed dose were 1.8-3 Gy and 36-70.4 Gy 
respectively. Twelve patients reported white, 11, blue, 2, 
yellow and 2, gray color visions. Seven patients experienced 
more than one color, while 2 patients did not attribute any 
special color to their light seeing experiences. Four patients 
had a kind of smell experience and 1 patient had a taste 
experience. 
 
Conclusion: Cherenkov radiation in eye ballsmay be the 
origin of light seeing experiences in patients receiving 
radiation treatment for head and neck malignancies, since 
treatmentsareperformed with ionizing radiations with 
energycapable to produce this effect. Also this effectmay be 
due to phosphenes produced by radiation treatment in 
different parts of the visual pathway (from retina to visual 
cortex). In order to investigate the mechanism of this 
phenomenon in patients and to define a radiation dose 
threshold – if the origin of this phenomenon is phosphenes 
produced in visual pathway – larger studies are needed. 
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Purpose or Objective: Ependymomas are central nervous 
system (CNS) tumors that due to their rare prevalence have 
considerable controversy regarding their prognostic factors 
and clinical management. As such, many of the reported 
series involve accumulation of patient data that spans many 
decades, making current management decisions difficult. In 
this study, we report the outcomes and possible prognostic 
factors of patients with histologically confirmed 
infratentorial ependymomas treated in the modern era. 
 
Material and Methods: A retrospective chart review of our 
patient registry was conducted to identify 15 patients 
diagnosed with infratentorial ependymoma between 2007—
2013. Mean age at diagnosis was 29 years (range 1.0—79.0 
years). There were 8 males and 7 females, with headache 
being the most common presenting symptom among the 
entire cohort. Eleven were newly diagnosed with 
ependymoma and the remaining 4 were recurrent patients 
who had failed primary therapy. Of the newly diagnosed 
patients, all received surgery and post-operative radiation 
therapy (RT) with a mean dose of 54.3 Gy (range 45.0—59.4 
Gy). Two also received chemotherapy. Patients in the 
recurrent group experienced only local recurrences after 
initial treatment and underwent salvage RT with a mean dose 
of 45.6 Gy (range 15.0—59.4 Gy). 
 
Results: With a mean follow-up time of 15 months (range 
1.4—61.7 months) for the cohort, a significant difference in 
overall survival (OS) was found between primary and 
recurrent patients (p=0.0082). Overall, 9 patients (60%) had 
no acute complications with the remainder Grade I or II 
following initial treatment. All were free of late 
complications throughout follow-up. Moreover, there were no 
statistically significant differences in OS or local control 
when tumor size or RT dose were analyzed.  
 
Conclusion: Our findings indicate that recurrence is a 
prognostic factor for decreased OS in patients with 
infratentorial ependymomas. Involved field radiation therapy 
following surgical resection of these tumors offers high local 
